Swedish translation and linguistic validation of the multidimensional dyspnoea profile

Article English OPEN
Ekström, Magnus ; Sundh, Josefin (2016)
  • Publisher: Co-Action Publishing
  • Journal: European Clinical Respiratory Journal (vol: 3)
  • Related identifiers: doi: 10.3402/ecrj.v3i0.32665, doi: 10.3402/ecrj.v3.32665, pmc: PMC5103669
  • Subject: Swedish | Dyspnea; Breathlessness; Multidimensional; Respiratory disease; Heart disease; Measurement; Swedish | respiratory disease | heart disease | Original Research Article | breathlessness | dyspnoea | multidimensional | measurement

Background: Dyspnoea, the feeling of breathing discomfort, consists of multiple dimensions that can vary in intensity, including the level of unpleasantness, qualities or descriptors of the sensation, emotional responses, and impact on function. No validated instrument for multidimensional measurement of dyspnoea is available in Swedish. The Multidimensional Dyspnea Profile (MDP) was recently developed to measure the unpleasantness, sensory qualities, and emotional responses of dyspnoea across diseases and settings. We aimed to take forward a Swedish version of the MDP.Methods: Translation and linguistic validation of the MDP was conducted in collaboration with a specialised company in the field (Mapi, Lyon, France). The structured process involved forward and backward translations by two independent certified translators, input from an in-country linguistic consultant, the developers, and three respiratory physicians. Understandability and acceptability were evaluated through in-depth interviews with five patients with dyspnoea in accordance with international guidelines.Results and Conclusion: A Swedish version of the MDP was obtained and linguistically validated. The MDP includes 11 rated items: the immediate unpleasantness of the sensation, the presence and intensity of five sensory qualities, and the intensity of five emotional responses to dyspnoea. The time period of measurement is specified by the user. The MDP is copyrighted by the developers but can be used free of charge in the context of non-funded academic research.Conclusion: The MDP is the first instrument for measuring multiple dimensions of dyspnoea available in Swedish and should be validated across diseases and settings. Multidimensional measurement is essential for improved assessment and management of dyspnoea in research and clinical care.Keywords: dyspnoea; breathlessness; multidimensional; respiratory disease; heart disease; measurement; Swedish(Published: 8 November 2016)Citation: European Clinical Respiratory Journal 2016, 3: 32665 - http://dx.doi.org/10.3402/ecrj.v3.32665
  • References (18)
    18 references, page 1 of 2

    1. Parshall MB, Schwartzstein RM, Adams L, Banzett RB, Manning HL, Bourbeau J, et al. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med. 2012; 185: 435 52.

    2. Gronseth R, Vollmer WM, Hardie JA, Olafsdottir IS, Lamprecht B, Buist AS, et al. Predictors of dyspnoea prevalence: results from the BOLD study. Eur Respir J. 2014; 43: 1610 20.

    3. Moens K, Higginson IJ, Harding R. Are there differences in the prevalence of palliative care-related problems in people living with advanced cancer and eight non-cancer conditions? A systematic review. J Pain Symptom Manag. 2014; 48: 660 77.

    4. Ekstrom MP, Abernethy AP, Currow DC. The management of chronic breathlessness in patients with advanced and terminal illness. BMJ. 2015; 349: g7617.

    5. From the global strategy for the diagnosis, management and prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD); 2016. Available from: http://wwwGold copdOrg/ [cited 31 October 2016].

    6. Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest. 2002; 121: 1434 40.

    7. Ahmed A, Aronow WS, Fleg JL. Higher New York Heart Association classes and increased mortality and hospitalization in heart failure patients with preserved left ventricular function. Am Heart J. 2006; 151: 444 50.

    8. Abidov A, Rozanski A, Hachamovitch R, Hayes SW, AboulEnein F, Cohen I, et al. Prognostic significance of dyspnea in patients referred for cardiac stress testing. N Engl J Med. 2005; 353: 1889 98.

    9. Johnson MJ, Currow DC, Booth S. Prevalence and assessment of breathlessness in the clinical setting. Expert Rev Respir Med. 2014; 8: 151 61.

    10. Banzett RB, O'Donnell CR, Guilfoyle TE, Parshall MB, Schwartzstein RM, Meek PM, et al. Multidimensional dyspnea profile: an instrument for clinical and laboratory research. Eur Respir J. 2015; 45: 1681 91.

  • Metrics
    No metrics available
Share - Bookmark